Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives

Ribeiro, Ronaldo A.; Wanderley, Carlos W.; Wong, Deysi Viviana Tenazoa; Mota, José Maurício; Leite, Caio A.; Souza, Marcellus H.; Cunha, Fernando; Lima-Júnior, Roberto César Pereira

doi:10.1007/s00280-016-3139-y

Cited by 126 publications

(113 citation statements)

References 89 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…1139–1145) in which TNF, IL-1β, and IL-6 levels were all elevated prior to tissue changes (Logan et al, 2008). Likewise, proteins associated with apoptosis (i.e., Bcl-2) regulation are impacted by a range of cytotoxic agents (Ribeiro et al, 2016). …”

Section: Pathobiology Of Mucositismentioning

confidence: 99%

“…Early-onset diarrhea is due to the activation of parasympathetic system leading to cholinergic syndrome by the inhibition of acetylcholinesterase or the release of large quantities of acetylcholine. On the other hand, late-onset diarrhea appears to be multifactorial with both cytokines and direct toxic inflammatory-mediated effects on the mucosa as well as motility alteration (Ribeiro et al, 2016). …”

Section: Pathobiology Of Mucositismentioning

confidence: 99%

“…In some cases malnutrition, dehydration, infections, and sepsis may also occur (Al-Dasooqi et al, 2013; Ribeiro et al, 2016). Typhlitis, otherwise known as neutropenic enterocolitis, is a mucositis of ileo-cecal region with high mortality risk, typically affecting patients with neutropenic fever.…”

Section: Clinical Presentationmentioning

confidence: 99%

See 2 more Smart Citations

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

et al. 2017

View full text Add to dashboard Cite

Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents. It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment. Moreover, the economic impact related to the management of mucositis is topical and several estimations of additional hospital costs due to this clinical condition have been recently reported. The ability to determine risk factors for mucositis, to early detect its onset, to assess correctly the degree of this toxicity and to plan its multidisciplinary management are all key elements to guarantee the quality of life of patients and to avoid useless dose reduction or interruption of treatment. The pathogenesis of mucositis is multifactorial and it is classily subdivided into oral and gastrointestinal mucositis according to its anatomic presentation. Treatment and patients’ related factors might help in predicting the frequency and the potential degree of symptoms onset. Here we discuss about clinical presentation and pathogenesis of mucositis in relation to different kinds of treatments. Moreover, we focus on therapeutic and prevention strategies, describing past and present management according to international guidelines and the most promising new data about agents potentially able to further improve the treatment of mucositis in the next future.

show abstract

Section: Pathobiology Of Mucositismentioning

confidence: 99%

Section: Pathobiology Of Mucositismentioning

confidence: 99%

See 1 more Smart Citation

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The options for treating such disorders remain limited (7,8). Ideally, medications used to correct toxic effects should not have side effects themselves, nor should they increase or decrease treatment effectiveness.…”

Section: Introductionmentioning

confidence: 99%

Effect of the polyphenol composition BP‑C3 on haematological and intestinal indicators of 5‑fluorouracil toxicity in mice

Panchenko

Fedoros

Pigarev³

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Abstract. BP-C3 is a formulation, which comprises lignin-derived polyphenolic composition of benzenepolycarboxylic acids (BP-Cx-1) with iron complex, selenium, ascorbic acid and retinol, and possesses geroprotective activity. The present study examined the effect of BP-C3 (80 mg/kg, administered 18 times in total by gavage) on the development of haematological and intestinal manifestations of toxicity following 5-fluorouracil (5-FU; 150 mg/kg, administered once via intravenous injection) administration in outbred male Swiss-H Rappolovo (SHR) mice. The use of BP-C3 on therapeutic and preventative/therapeutic schedules demonstrated that it was protective against the toxic effect of 5-FU exerted on the lymphopoietic organs. Administering ВР-С3 24 h after 5-FU (therapeutic schedule) had an effect on the recovery of leukopoiesis and prevented anaemia in the mice. In the mice that received 5-FU and 5-FU with BP-C3 prior to and following administration of the chemotherapeutic agent (preventative/therapeutic schedule), mild anaemia developed by day 7. Administration of BP-C3 without 5-FU did not affect blood cell differentiation in the mice. Thus, BP-C3, depending on the administration schedule, had different effects on the haematological parameters of haematopoietic organs and peripheral blood in mice exposed to 5-FU. BP-C3 promoted intestinal crypt survival when administered on the preventative/therapeutic and therapeutic schedules, suggesting that the formulation protects the epithelium of the small intestine against damage by 5-FU.

show abstract

“…Intestinal mucositis is a common side effect of anti-cancer drugs [1]. The antimetabolite anticancer agent 5-fluorouracil (5-FU) is widely used to treat malignancies as it improves tumor-free status and survival rates [2].…”

Section: Introductionmentioning

confidence: 99%

Oral Administration of Surface-Deacetylated Chitin Nanofibers and Chitosan Inhibit 5-Fluorouracil-Induced Intestinal Mucositis in Mice

Koizumi

Aso

Izawa

et al. 2017

IJMS

View full text Add to dashboard Cite

This study investigated the prophylactic effects of orally administered surface-deacetylated chitin nanofibers (SDACNFs) and chitosan against 5-fluorouracil (5-FU)-induced intestinal mucositis, which is a common side effect of 5-FU chemotherapy. SDACNFs and chitosan abolished histological abnormalities associated with intestinal mucositis and suppressed hypoproliferation and apoptosis of intestinal crypt cells. These results indicate that SDACNF and chitosan are useful agents for preventing mucositis induced by anti-cancer drugs.

show abstract

Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives

Cited by 126 publications

References 89 publications

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

Effect of the polyphenol composition BP‑C3 on haematological and intestinal indicators of 5‑fluorouracil toxicity in mice

Oral Administration of Surface-Deacetylated Chitin Nanofibers and Chitosan Inhibit 5-Fluorouracil-Induced Intestinal Mucositis in Mice

Contact Info

Product

Resources

About